Calculate levothyroxine (Synthroid) dose by weight, age, and indication with TSH-based dose adjustment, pregnancy dosing, alternating-day schedules, and tablet strength selection.
Levothyroxine is the most widely prescribed medication for hypothyroidism and is the standard of care for thyroid hormone replacement. Correct dosing depends on body weight, age, indication (replacement vs. TSH suppression for thyroid cancer), cardiac status, and pregnancy — with ongoing TSH monitoring guiding dose adjustments every 6–8 weeks until the target range is achieved.
This levothyroxine dosage calculator uses evidence-based weight-based factors for nine age and risk categories, from neonates (10–15 mcg/kg/day) through elderly and cardiac patients (0.5–1.0 mcg/kg/day), and includes automatic pregnancy dose adjustment (+30%), alternating-day tablet scheduling when the ideal dose falls between available strengths, TSH-guided dose titration recommendations, and comprehensive reference tables for tablet colors, drug interactions, and monitoring intervals.
Full thyroid replacement in healthy young adults requires approximately 1.6 mcg/kg/day of levothyroxine. However, elderly patients and those with coronary artery disease should be started at 12.5–25 mcg/day and titrated slowly to avoid precipitating angina, arrhythmias, or myocardial infarction. Pregnant women typically need a 30–50% dose increase immediately upon confirmation of pregnancy, with TSH monitoring every 4 weeks through the first half of pregnancy, as inadequate thyroid hormone can impair fetal neurodevelopment.
Levothyroxine is available in 12 precise tablet strengths, and the ideal weight-based dose rarely matches a single tablet exactly. This calculator bridges the gap between the calculated dose and available options — including alternating-day schedules, pregnancy adjustments, and TSH-guided titration — providing a complete dosing decision tool for both initiation and ongoing management.
Levothyroxine dose (mcg/day) = weight (kg) × age-based factor (mcg/kg/day). Full replacement: ~1.6 mcg/kg/day. Elderly: ~1.0 mcg/kg/day. Cardiac: start 12.5–25 mcg/day. Pregnancy adjustment: multiply by 1.3. TSH suppression (thyroid cancer): ~2.2 mcg/kg/day. Available tablets: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg.
Result: 112 mcg/day (estimated 112 mcg, closest tablet = 112 mcg).
A 70 kg adult: 70 × 1.6 = 112 mcg/day. The nearest tablet is exactly 112 mcg (rose-colored Synthroid). Weekly dose: 784 mcg. TSH should be rechecked in 6–8 weeks.
Levothyroxine (T4) is a prohormone that is peripherally converted to the active hormone triiodothyronine (T3) by deiodinase enzymes in target tissues. This conversion provides a stable, predictable T3 supply unlike direct T3 administration, which causes peaks and troughs. Levothyroxine has a long half-life of approximately 7 days, meaning steady-state levels are reached in 5–6 weeks after any dose change. This pharmacokinetic profile is why TSH should not be rechecked sooner than 6 weeks.
Absorption occurs primarily in the jejunum and ileum and requires an acidic gastric pH. Conditions that reduce gastric acid (atrophic gastritis, H. pylori infection, PPI use, bariatric surgery) can impair absorption by 20–40%, necessitating higher doses. Celiac disease, lactose intolerance (in lactose-containing formulations), and inflammatory bowel disease similarly affect absorption.
**Neonates:** Congenital hypothyroidism requires immediate and aggressive replacement (10–15 mcg/kg/day) to prevent intellectual disability. T4 should be normalized within 2 weeks of birth. Liquid preparation or crushed tablets in breast milk are used.
**Thyroid Cancer:** TSH suppression (goal <0.1 mIU/L for high-risk, 0.1–0.5 for intermediate-risk) requires supra-physiologic doses of 2.0–2.5 mcg/kg/day. Yearly reassessment of suppression goals is recommended, with de-escalation as recurrence risk declines.
**Subclinical Hypothyroidism:** Treatment is recommended when TSH >10 mIU/L, and considered when TSH is 4–10 with symptoms, positive TPO antibodies, hyperlipidemia, or infertility. In elderly patients (>70 years), TSH 4–7 may be a normal aging variation and treatment is often not beneficial.
The standard monitoring protocol involves checking TSH 6–8 weeks after initiation, then every 6–12 months once stable. Dose adjustments of 12.5–25 mcg are typical for TSH values outside the reference range. If a patient's TSH fluctuates despite consistent dosing, investigate adherence, timing relative to meals, drug interactions, formulation changes, and malabsorption. Free T4 levels add clinical value when TSH is discordant with symptoms or in the setting of pituitary disease (where TSH is unreliable).
Levothyroxine should be taken on an empty stomach, ideally 30–60 minutes before breakfast or at bedtime (at least 3 hours after the last meal). Consistency in timing is more important than the specific time of day. Some patients take it with water before getting out of bed for best absorption.
After starting or changing a dose, check TSH in 6–8 weeks (it takes this long for serum levels to equilibrate). Once stable, TSH can be monitored every 6–12 months. During pregnancy, check every 4 weeks through week 20, then at least once at 30 weeks.
Elderly patients, especially those with cardiac disease, are at risk for angina, atrial fibrillation, and myocardial infarction if thyroid replacement is initiated too rapidly. Starting at 12.5–25 mcg/day and increasing by 12.5–25 mcg every 6–8 weeks allows gradual metabolic adjustment. Full replacement may never be achieved in some cardiac patients.
Pregnancy increases thyroid-binding globulin (TBG) levels due to estrogen, reducing free T4 availability. Additionally, the fetus depends on maternal thyroid hormone during the first trimester. Guidelines recommend increasing the dose by 30–50% as soon as pregnancy is confirmed and maintaining TSH below 2.5 mIU/L (per ATA guidelines) in the first trimester.
While bioequivalent by FDA standards, different formulations may have slightly different absorption characteristics. The ATA recommends rechecking TSH 6–8 weeks after any brand/generic switch. If TSH is sensitive to small dose changes, maintaining a consistent brand is advisable. Tirosint (gel capsule) or liquid formulations may improve absorption in patients with GI disorders.
When the ideal dose falls between available tablet strengths (e.g., 137 mcg needed but only 125 and 150 available), alternating tablets on specific days achieves the target weekly dose. For example: 150 mcg on 3 days/week + 125 mcg on 4 days/week = 950 mcg/week = ~136 mcg/day average. This avoids cutting tablets, which can cause inconsistent dosing.